These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 24981842)

  • 21. A multiplexed approach to hit finding.
    Slack M; Winkler D; Krämer J; Hesterkamp T
    Curr Opin Drug Discov Devel; 2009 May; 12(3):351-7. PubMed ID: 19396736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Live cell imaging: an industrial perspective.
    McCann T
    Methods Mol Biol; 2010; 591():47-66. PubMed ID: 19957123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel fluorescent proteins for high-content screening.
    Wolff M; Wiedenmann J; Nienhaus GU; Valler M; Heilker R
    Drug Discov Today; 2006 Dec; 11(23-24):1054-60. PubMed ID: 17129823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The utility of semi-automating multiplexed assays for ADME/Tox applications.
    Larson B; Banks P; Shultz S; Sobol M; Cali JJ
    Comb Chem High Throughput Screen; 2011 Sep; 14(8):658-68. PubMed ID: 21564019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stem cells as screening tools in drug discovery.
    McNeish JD
    Curr Opin Pharmacol; 2007 Oct; 7(5):515-20. PubMed ID: 17681491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-throughput screening: update on practices and success.
    Fox S; Farr-Jones S; Sopchak L; Boggs A; Nicely HW; Khoury R; Biros M
    J Biomol Screen; 2006 Oct; 11(7):864-9. PubMed ID: 16973922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection and classification of threat agents via high-content assays of mammalian cells.
    Tencza SB; Sipe MA
    J Appl Toxicol; 2004; 24(5):371-7. PubMed ID: 15478183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of diversity-based, high-throughput screening on drug discovery: "chance favours the prepared mind".
    Snowden M; Green DV
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):553-8. PubMed ID: 18600571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of variability and sensitivity between nuclear translocation and luciferase reporter gene assays.
    Unterreiner V; Ibig-Rehm Y; Simonen M; Gubler H; Gabriel D
    J Biomol Screen; 2009 Jan; 14(1):59-65. PubMed ID: 19171921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel trends in high-throughput screening.
    Mayr LM; Bojanic D
    Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High content screening as a screening tool in drug discovery.
    Nichols A
    Methods Mol Biol; 2007; 356():379-87. PubMed ID: 16988417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of the mirrorball high-sensitivity cytometer to multiplexed assays for antibody drug discovery.
    England E; Newton P; Neal F; Kitching L; Colley C; Rossant CJ
    J Biomol Screen; 2015 Apr; 20(4):536-44. PubMed ID: 25381256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrated expressional analysis: application to the drug discovery process.
    Ilyin SE; Horowitz D; Belkowski SM; Xin H; Eckardt AJ; Darrow AL; Chen C; Maley D; D'Andrea M; Plata-Salamán CR; Derian CK
    Methods; 2005 Nov; 37(3):280-8. PubMed ID: 16308157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early safety assessment using cellular systems biology yields insights into mechanisms of action.
    Giuliano KA; Gough AH; Taylor DL; Vernetti LA; Johnston PA
    J Biomol Screen; 2010 Aug; 15(7):783-97. PubMed ID: 20639501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of a rapid and integrated analysis system (RIAS) as a high-throughput processing tool for in vitro ADME samples by liquid chromatography/tandem mass spectrometry.
    Luippold AH; Arnhold T; Jörg W; Krüger B; Süssmuth RD
    J Biomol Screen; 2011 Mar; 16(3):370-7. PubMed ID: 21335598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Past, present, and future of high content screening and the field of cellomics.
    Taylor DL
    Methods Mol Biol; 2007; 356():3-18. PubMed ID: 16988391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Techniques: application of systems biology to absorption, distribution, metabolism, excretion and toxicity.
    Ekins S; Nikolsky Y; Nikolskaya T
    Trends Pharmacol Sci; 2005 Apr; 26(4):202-9. PubMed ID: 15808345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CellProfiler and KNIME: open source tools for high content screening.
    Stöter M; Niederlein A; Barsacchi R; Meyenhofer F; Brandl H; Bickle M
    Methods Mol Biol; 2013; 986():105-22. PubMed ID: 23436409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.